Eli Lilly & Co. (LLY) Tops Q3 EPS by 7c; Offers FY22 EPS Guidance

Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.98, $0.07 better than the analyst estimate of $1.91. Revenue for the quarter came in at $6.94 billion versus the consensus estimate of $6.91 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2022 EPS of $7.70-$7.85, versus the consensus of $7.99.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
• Constellation Brands (STZ) Tops Q1 EPS by 18c
• FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance